BRIEF published on 07/30/2026 at 21:35, 9 days 17 hours ago Poxel Records Positive Turnover amidst Financial Statement Postponement Financial Statements Royalties Poxel TWYMEEG® Sales Debt Valuation
BRIEF published on 07/30/2026 at 21:35, 9 days 17 hours ago Poxel: Q2 2026 Results and 2025 Financial Statements Report Revenue TWYMEEG® Poxel Sumitomo Pharma 2025 Accounts
PRESS RELEASE published on 07/30/2026 at 21:30, 9 days 17 hours ago Inside Information / Other news releases Poxel publishes Q2 2026 turnover & delays 2025 financial statements release. TWYMEEG(R) net sales up in Japan, reaching 2.9 billion yen; royalty rate to increase Financial Statements Turnover Royalties Poxel TWYMEEG
BRIEF published on 06/10/2026 at 20:18, 1 month 28 days ago Poxel appoints Yves Decadt as its new Chief Executive Officer Strategic Partnerships Biopharmaceutical Continuation Plan Poxel Yves Decadt
BRIEF published on 06/10/2026 at 20:18, 1 month 28 days ago Poxel Appoints Yves Decadt as CEO to Advance Strategic Goals Strategic Partnerships Biopharmaceutical Poxel Imeglimin Yves Decadt
PRESS RELEASE published on 06/10/2026 at 20:13, 1 month 28 days ago Inside Information / Other news releases Poxel appoints Yves Decadt as Chief Executive Officer to accelerate portfolio development and strategic partnerships. Yves Decadt brings over 25 years of international pharmaceutical industry experience Strategic Partnerships Chief Executive Officer Portfolio Development Poxel Yves Decadt
BRIEF published on 03/31/2026 at 13:12, 4 months 9 days ago Poxel sells the PXL770 to Scynexis for a potential value of $196 million Financial Agreement Poxel PXL770 SCYNEXIS Polycystic Kidney Disease
BRIEF published on 03/31/2026 at 13:12, 4 months 9 days ago Poxel Sells PXL770 to Scynexis for Up to $196 Million Biopharmaceutical Poxel PXL770 SCYNEXIS ADPKD
PRESS RELEASE published on 03/31/2026 at 13:07, 4 months 9 days ago Inside Information / Operations of the issuer (acquisitions, sales...) Poxel announces sale of PXL770 for up to $196 million to SCYNEXIS. PXL770 targets ADPKD. Agreement includes upfront payment, development and commercial milestones. Phase 2 study planned for Q4 2026 Milestones Poxel PXL770 SCYNEXIS ADPKD
BRIEF published on 03/25/2026 at 22:03, 4 months 14 days ago Poxel Secures Additional Financing Through New Tranche D PDR Bonds Financing Continuation Plan Poxel IPF Partners Tranche D PDR
Published on 08/07/2026 at 23:15, 1 day 15 hours ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 1 day 16 hours ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 1 day 16 hours ago UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 1 day 16 hours ago Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services
Published on 08/09/2026 at 15:05, 8 minutes ago GearUP and Escape from Tarkov Partner to Enhance Online Gaming Experience for the New Season
Published on 08/09/2026 at 00:01, 15 hours 13 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 08/08/2026 at 16:25, 22 hours 48 minutes ago Bybit Sues North Korea and Lazarus Group, Secures Preliminary Injunction Freezing Stolen Assets in Landmark Crypto Asset Recovery Effort
Published on 08/07/2026 at 23:21, 1 day 15 hours ago EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration
Published on 08/07/2026 at 19:30, 1 day 19 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/07/2026 at 18:54, 1 day 20 hours ago Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 1 day 20 hours ago Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 17:49, 1 day 21 hours ago Crédit Agricole CIB announced the publication of the Amendment of its 2025 Universal Registration Document
Published on 08/07/2026 at 08:30, 2 days 6 hours ago Disclosure of shares outstanding and voting rights - 07.08.2026
